Global Pancreatic cancer Market Research Report- Forecast To 2022

Global Pancreatic cancer Market Research Report- Forecast To 2022

ID: MRFR/HC/1107-HCRR | July, 2017 | Region: Global | 110 pages | Half-Cooked Research Reports

Global Pancreatic cancer Information, by type (endocrine pancreas cancer, exocrine pancreas cancer and others), by treatment type (surgery, chemotherapy, radiation therapy and others), by end users (hospital, clinics, research institutes and others) - Forecast to 2022


Study Objectives of Pancreatic cancer Market:



  • To provide detailed analysis of the market structure along with forecast for the next 7 years of the various segments and sub-segments of the Pancreatic cancer market

  • To provide insights about factors affecting the market growth

  • To analyze the pancreatic cancer market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size and future prospective

  • To provide country level analysis of the market for segments by type, by treatment type, by end users and its sub-segments.

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global pancreatic cancer market.


Intended Audience:



  • Companies into Pancreatic cancer  

  • Research and Development (R&D) Companies

  • Independent Research Laboratories

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories


Market Synopsis of Pancreatic cancer market:


Market Scenario:


Cancer starts when cells in the body begin to grow out of control. Pancreatic cancer starts when cells in the pancreas start to grow uncontrollably.  It causes Symptoms like abdominal pain, weight loss, diarrhea, and jaundice.  The tumor hinders the normal functioning of pancreas. The biggest risk factor for developing pancreatic cancer is smoking. To diagnose the cancer doctor will do a complete physical exam and history check and then blood, urine, and stool tests may be done.


Market for Pancreatic cancer is growing as there is an increase in the consumption of alcohol, smoking and change is lifestyle. The global market for Pancreatic cancer is expected to reach US$ XX by the end of the forecasted period and is expected to grow at a CAGR of XX%.


Segments:


Global Pancreatic cancer market has been segmented on the basis of type which comprise of endocrine pancreas cancer, exocrine pancreas cancer and others. On the basis of treatment type; market is segmented into; surgery, radiation therapy, chemotherapy and others. On the basis of end users; market is segmented as; hospital, clinics, research institutes and others.


Regional Analysis of Pancreatic cancer Market:


Globally North America is the largest market for pancreatic cancer. The North American market for Pancreatic cancer is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. The prevalence of pancreatic cancer is more in North American countries.


Europe is expected to be the second-largest market for pancreatic cancer which is expected to grow at a CAGR of XX%. Asia-Pacific is anticipated to be the fastest growing region across the globe, and is expected to grow at a CAGR of XX% during the forecasted period.


Key Players for Pancreatic cancer market:


Some of the key players in this market are: PharmaCyte Biotech Inc. (US), OncoGenex Pharmaceuticals Inc., Oncolytics Biotech (Canada), DiffusionPharmaceuticals (US), Polaris Pharmaceuticals, Inc., Sun BioPharma, Inc., Midatech Pharma PLC (UK) and others.


Global Pancreatic Cancer by Region


North America



  • US

  • Canada


Europe



  • Western Europe

  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia



  • China

  • India

  • Japan

  • South Korea

  • Rest of Asia


Pacific


Latin America, Middle East & Africa


The report for Global Pancreatic cancer Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions


 


 

1    INTRODUCTION    

      1.1    DEFINITION    

      1.2    SCOPE OF STUDY    

            1.2.1    RESEARCH OBJECTIVE    

            1.2.2    ASSUMPTIONS & LIMITATIONS    

                1.2.2.1    ASSUMPTIONS    

                1.2.2.2    LIMITATIONS    

      1.3    MARKET STRUCTURE:    

2    RESEARCH METHODOLOGY    

      2.1    RESEARCH PROCESS:    

      2.2    PRIMARY RESEARCH    

      2.3    SECONDARY RESEARCH:    

3    MARKET DYNAMICS    

      3.1    DRIVERS    

      3.2    RESTRAINTS        

      3.3    OPPORTUNITIES    

      3.4    MACROECONOMIC INDICATORS    

4    MARKET FACTOR ANALYSIS    

      4.1    PORTERS FIVE FORCES MODEL    

      4.2    BARGAINING POWER OF SUPPLIERS    

      4.3    BARGAINING POWER OF BUYERS    

      4.4    THREAT OF NEW ENTRANTS    

      4.5    THREAT OF SUBSTITUTES    

      4.6    INTENSITY OF RIVALRY    

5.    GLOBAL PANCREATIC CANCER MARKET, BY TYPE

      5.1    ENDOCRINE PANCREAS CANCER

      5.2    EXOCRINE PANCREAS CANCER

      5.3    OTHERS

6.    GLOBAL PANCREATIC CANCER MARKET, BY TREATMENT

      6.1    CHEMOTHERAPY

            6.1.1    ANTIMETABOLITES

            6.1.2    ANTHRACYCLINES

            6.1.3    TAXANES

            6.1.4    ALKYLATING AGENTS.

      6.2    SURGERY & RADIATION THERAPY

      6.3    TARGETED THERAPY

            6.3.1    TYROSINE KINASE INHIBITORS

            6.3.2    MONOCLONAL ANTIBODIES

      6.4    BIOLOGIC THERAPY

      6.5    HORMONE THERAPY

            6.5.1    ESTROGEN-RECEPTOR MODULATORS

            6.5.2    AROMATASE INHIBITORS

            6.5.3    OTHERS

7.    GLOBAL PANCREATIC CANCER MARKET, BY END USERS

      7.1    HOSPITALS AND CLINICS

      7.2    REASERCH INSTITUTE

      7.3    OTHER

8.     GLOBAL PANCREATIC CANCER MARKET, BY REGION

      8.1    INTRODUCTION

      8.2    AMERICA

            8.2.1    NORTH AMERICA

                8.2.1.1  US

                8.2.1.2  CANADA

            8.2.2    SOUTH AMERICA

      8.3    EUROPE

            8.3.1    WESTERN EUROPE

                8.3.1.1  GERMANY

                8.3.1.2  FRANCE

                8.3.1.3 I TALY

                8.3.1.3  SPAIN

                8.3.1.5  UK

                8.3.1.6  REST OF WESTERN EUROPE

            8.3.2    EASTERN EUROPE

      8.4    ASIA-PACIFIC

            8.4.1    JAPAN

            8.4.2    CHINA

            8.4.3    INDIA

            8.4.4    AUSTRALIA

            8.4.5    REPUBLIC OF KOREA

            8.4.6    REST OF ASIA-PACIFIC

      8.5    MIDDLE EAST & AFRICA

            8.5.1    UNITED ARAB EMIRATES

            8.5.2     SAUDI ARABIA

            8.5.3    OMAN

            8.5.4    KUWAIT

            8.5.5    QATAR

            8.5.6    REST OF MIDDLE EAST & AFRICA

9.    COMPETITIVE LANDSCAPE    

      9.1    MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS    

            9.1.1    STRATEGIC PARTNERSHIP    

            9.1.2    MERGER & ACQUISITION    

10    COMPANY PROFILE    

      10.1    ELI LILLY AND COMPANY.

            10.1.1    OVERVIEW    

            10.1.2    PRODUCT OVERVIEW    

            10.1.3    FINANCIALS    

            10.1.4    KEY DEVELOPMENTS    

      10.2    CELGENE CORPORATION.

            10.2.1    OVERVIEW    

            10.2.2    PRODUCT OVERVIEW    

            10.2.3    FINANCIALS    

            10.2.4    KEY DEVELOPMENTS    

      10.3    F. HOFFMANN-LA ROCHE AG.

            10.3.1    OVERVIEW

            10.3.2    PRODUCT OVERVIEW    

            10.3.3    FINANCIALS

            10.3.4    KEY DEVELOPMENT    

      10.4    AMGEN, INC.

            10.4.1    OVERVIEW

            10.4.2    PRODUCT OVERVIEW

            10.4.3    FINANCIALS

            10.4.4    KEY DEVELOPMENTS    

      10.5     NOVARTIS AG

            10.5.1    OVERVIEW

            10.5.2    PRODUCT OVERVIEW    

            10.5.3    FINANCIALS    

            10.5.4    KEY DEVELOPMENTS    

      10.6    PHARMACYTE BIOTECH, INC

            10.6.1    OVERVIEW

            10.6.2    PRODUCT OVERVIEW    

            10.6.3    FINANCIALS    

            10.6.4    KEY DEVELOPMENTS    

      10.7    CLOVIS ONCOLOGY

            10.7.1    OVERVIEW

            10.7.2    PRODUCT OVERVIEW    

            10.7.3    FINANCIALS    

            10.7.4    KEY DEVELOPMENTS    

      10.8    MERCK & CO., INC

            10.8.1    OVERVIEW

            10.8.2    PRODUCT OVERVIEW    

            10.8.3    FINANCIALS    

            10.8.4    KEY DEVELOPMENTS    

      10.9    OTHERS

11         CONCLUSION

      11.1      KEY FINDINGS

            11.1.1   FROM CEO’S VIEWPOINT

            11.1.2   UNMET NEEDS OF THE MARKET

      11.2      KEY COMPANIES TO WATCH

      11.3      PREDICTION OF ONCOCARE INDUSTRY

12     APPENDIX